PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug may tame Life-Threatening side effects of cancer immunotherapy
Disease control CompletedThis study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental CAR-T therapy takes on tough lymphomas
Disease control CompletedThis early-phase trial tested a new treatment called BZ019, made from a patient's own immune cells modified to attack cancer. It involved 12 adults with aggressive B-cell lymphomas that had not responded to standard therapy. The main goals were to check safety and see if the trea…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy shows promise for kids with rare lymphoma
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy drugs (etoposide, doxorubicin, vincristine, cyclophosphamide) plus the targeted drug rituximab in 47 children and teens with primary mediastinal large B-cell lymphoma. The goal was to see how well the regimen prevented the c…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Double attack on blood cancer: stem cell transplant plus CAR-T shows promise
Disease control CompletedThis study tested a new approach for adults with a tough-to-treat type of blood cancer called large B-cell lymphoma that had returned or not responded to prior treatment. Participants first received a stem cell transplant using their own cells, followed by infusions of two types …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Immune booster after CAR-T shows promise in early lymphoma trial
Disease control CompletedThis early-phase study tested an experimental drug called NT-I7 (efineptakin alfa) in 17 people with relapsed or refractory large B-cell lymphoma who had already received CAR-T cell therapy. The goal was to see if giving NT-I7 after CAR-T is safe and tolerable, and to look for ea…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spinal injection may shield brain from lymphoma spread
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Can a common arthritis drug tame CAR-T's dangerous side effects?
Symptom relief CompletedThis phase 2 trial tested whether adding the drug anakinra (Kineret) to standard CAR-T cell therapy could prevent nerve toxicity in 15 people with relapsed or refractory non-Hodgkin lymphoma. Participants received anakinra injections for a week alongside their CAR-T infusion. The…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC